Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease
Open Access
- 28 October 2025
- journal article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (20)
Abstract
CLN3 Batten disease is a lethal pediatric neurodegenerative disease caused by mutations in the CLN3 gene. Typically, the disease manifests as vision loss in early childhood and progresses to neurological dysfunction and death in young adulthood. Most therapeutic developments have focused on treating the brain and may not protect against vision loss, which greatly affects quality of life. We have previously shown that a splice-switching antisense oligonucleotide (ASO) delivered to the central nervous system can reduce neurological disease burden in mouse models of CLN3 disease. Here, we apply a similar ASO approach for treating retinal dysfunction in a pig model of CLN3 Batten disease, which is more representative of human vision. A single intravitreal injection of ASO induces robust exon skipping in the retina for up to 12 months. The ASO treatment resulted in higher amplitudes on electroretinograms, suggesting mitigation of retinal dysfunction at early timepoints of disease. One ASO that efficiently induces exon skipping in vivo was well-tolerated and targets a region conserved in humans, making it a promising candidate for clinical translation. Our findings demonstrate the utility of an ASO-based approach to treat retinal dysfunction in CLN3 Batten disease and support broader ASO applications for treating ocular diseases.Keywords
Funding Information
- National Institutes of Health (NS113233)
- Batten Disease Support and Research Association
- RFUMS
- National Institutes of Health (S10 OD010662)
This publication has 74 references indexed in Scilit:
- Full-field ERG in patients with Batten/Spielmeyer-Vogt disease caused by mutations in the CLN3 geneOphthalmic Genetics, 2000
- Expression of cln3 in Human NT2 Neuronal Precursor Cells and Neonatal Rat BrainPediatric Research, 1999
- Analysis of Intracellular Distribution and Trafficking of the CLN3 Protein in Fusion with the Green Fluorescent Proteinin VitroMolecular Genetics and Metabolism, 1999
- Retinal Degeneration in Retinitis Pigmentosa and Neuronal Ceroid Lipofuscinosis: An OverviewMolecular Genetics and Metabolism, 1999
- The dystrophic retina in multisystem disorders: The electroretinogram in neuronal ceroid lipofuscinosesEye, 1998
- Spectrum of Mutations in the Batten Disease Gene, CLN3The American Journal of Human Genetics, 1997
- 2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial CellsJournal of Biological Chemistry, 1997
- Isolation of a novel gene underlying batten disease, CLN3Cell, 1995
- Multiple sequence alignment with hierarchical clusteringNucleic Acids Research, 1988
- The Fine Structure of the Retina in Neuronal Ceroid-LipofuscinosisAmerican Journal of Ophthalmology, 1974